The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer

Douglas K. Price, Jennifer R. Ball, Zahra Bahrani-Mostafavi, Judith C. Vachris, Jay S. Kaufman, R. Wendel Naumann, Robert V. Higgins, James B. Hall

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

To identify potential prognostic indicators of ovarian cancer and identify targets for therapeutic strategies, mRNA differential display was used to analyze gene expression differences in normal, benign, and cancerous ovarian tissue. One cDNA isolated by this technique, Op18/stathmin, is a highly conserved gene that is reported to have many different functions within a cell, including signal transduction, control of the cell cycle, and the regulation of microtubules. Quantitative Northern blot analysis of 12 malignant ovarian samples, 8 benign ovarian tumors, and 10 normal ovarian tissue samples demonstrated overexpression of Op18/stathmin mRNA in the malignant cancers. Immunohistochemistry showed an apparent overexpression of Op18/stathmin protein level and an association with proliferating cells.

Original languageEnglish (US)
Pages (from-to)722-730
Number of pages9
JournalCancer Investigation
Volume18
Issue number8
DOIs
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Price, D. K., Ball, J. R., Bahrani-Mostafavi, Z., Vachris, J. C., Kaufman, J. S., Naumann, R. W., Higgins, R. V., & Hall, J. B. (2000). The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Investigation, 18(8), 722-730. https://doi.org/10.3109/07357900009012204